The new research program initiated between Gubra and Sanofi builds upon the established research consortium between Gubra, Gentofte Hospital and the University of Copenhagen partly funded by the Danish National Advanced Technology foundation.
“We are delighted at the prospect of working with the Gubra target discovery team on this particular project,” said Philip Just Larsen, Head of Research and Translational Medicine of the Global Diabetes Division at Sanofi. “And we hope that this project which utilizes the comprehensive Gubra expertise in molecular pathways will open the door to the development of new treatments for patients with type 2 diabetes,” he added.
Niels Vrang, CEO at Gubra emphasized the importance of the research collaboration between Gubra and Sanofi: “This alliance will facilitate the development of new targets and new drugs and we are really happy that Sanofi realized the synergistic potential in our established research collaboration with Gentofte Hospital (Diabetes Research Division, Filip K. Knop) and University of Copenhagen (Department of Chemistry, Knud J. Jensen)”.
In 2012 Gubra, Gentofte and University of Copenhagen received partial funding from the Danish National Advanced Technology Foundation for a target/drug discovery project focusing on novel gut peptides. Under the terms of the agreement, Sanofi will provide Gubra research funding over the course of the collaboration. If certain developments, regulatory and commercial milestones are achieved, Gubra and their research partners will be entitled to receive payments, as well as royalties on worldwide product sales.
